<DOC>
	<DOCNO>NCT00496392</DOCNO>
	<brief_summary>Primary : • To compare efficacy nasal fentanyl ( NF ) oral transmucosal fentanyl ( Actiq® ) ( hereafter Actiq ) management breakthrough pain cancer patient . Secondary : - To compare patient ' general impression preference NF Actiq - To explore relationship NF dose dose current opioid breakthrough pain ( BTP ) relationship dose NF background opioid - To assess safety tolerability NF</brief_summary>
	<brief_title>Comparison Nasal Fentanyl Oral Transmucosal Fentanyl ( Actiq ) Cancer Breakthrough Pain ( FT-019-IM )</brief_title>
	<detailed_description />
	<mesh_term>Breakthrough Pain</mesh_term>
	<mesh_term>Fentanyl</mesh_term>
	<criteria>Adult patient cancer breakthrough pain ; use stable , chronic opioid treatment background pain . Minimum three BTP episode per week maximum four per day . Life expectancy least three month . Chemotherapy palliative radiotherapy ( except facial radiotherapy ) allow . Randomisation previous study NF , i.e . FT016IM , FT017IM FT018IM , allow . Previous use Actiq accept .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>breakthrough pain patient cancer</keyword>
</DOC>